Jazz Pharmaceuticals plc — Biotechnology. Scored on the same transparent 7-signal model behind the daily rankings.
★
JAZZ
Jazz Pharmaceuticals plc · Biotechnology
FCF$1.3bC+
Rev+4.9%C+
D/E1.20C
P/S3.5xB
PEG0.96B+
54.4Score
$246.91$15.5B
1Y Target$256.89Analyst consensus · 19 analysts
5Y Target$449.31Compound horizon
10Y Target$1,139Long-dated conviction
FCF$1.3bTTMC+
FCF $1.3b — respectable but not differentiating
Rev+4.9%TTM YoYC+
Revenue +4.9% — steady but below market-beating range
D/E1.20C
D/E 1.20 — more levered than most Healthcare peers (≈90th pctile)
P/S3.5xB
P/S 3.5x — near the Healthcare median (≈60th pctile)
PEG0.96B+
PEG 0.96 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 54.4
Quality0.35
Growth0.60
Value0.76
Entry · Margin of safety
52-week rangeNear 52-week high
1% off the 12-month high
vs DCF fair value14% belowest. fair value ~$286
Quality signals · context only
ROIC-0.3% · Freturn on invested capital — not score-weighted
Why now
Biotechnology · market cap $15.5b. Trading near 52-week high of $250.49 — momentum setup, limited technical margin of safety. PEG 0.96 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $256.89 (implying +4% upside).
Moat
Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Net margin 0.7% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 1% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $256.89 (19-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $449.31 — requires the platform / technology to reach commercial scale. 10 yr $1,139 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · JAZZ
$
%
%
Shares to buy
8
Position size
$1,975
4.0% of portfolio
Stop price
$185.18
25% below $246.91
$ at risk if stopped
$493.82
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Jazz Pharmaceuticals plc (JAZZ): score, valuation & FAQ
Jazz Pharmaceuticals plc (JAZZ) is a Biotechnology company that scores 54.4 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are PEG (B+). On valuation, JAZZ sits about 14% below our discounted-cash-flow fair value (a margin of safety).
Is JAZZ a good stock to buy?
Bull Rankings scores JAZZ 54.4 out of 100 on its quality-growth model, which is a middling reading. That is driven by PEG (B+). A score is a quantitative screen of Jazz Pharmaceuticals plc's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does JAZZ score 54.4 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). JAZZ earns its highest marks on PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is JAZZ overvalued or undervalued?
Based on $246.91, JAZZ sits about 14% below our discounted-cash-flow fair value (a margin of safety). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in JAZZ?
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Net margin 0.7% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 1% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.